Introduction
The treatment of childhood pre-B ALL has improved dramatically over the past several decades, with a 5-year event-free survival of 20% in the early 1970s as compared to 70% in the 1990s. 1 However, during the past 10 years the survival curves have reached a plateau, and the outcome for the 30% of children who relapse remains poor. Refinements in the delineation of risk groups and alternative treatment regimens have improved survival for some patients, but there remains a pressing need for novel agents. Mabs, either 'naked' or conjugated to toxins (immunotoxins or ITs) have undergone clinical testing in adults with various malignancies. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] However, there are currently only two phase I studies utilizing ITs for the treatment of childhood leukemia and only one for Blineage ALL. 12 Mabs directed against the B cell surface antigens CD19 (HD37) and CD22 (RFB4) conjugated to dgRTA via the stable thiol-containing heterobifunctional linker, 4-succinimidyloxycarbonyl-␣-methyl-␣(2-pyridyldithio)toluene (SMPT) have been developed 13 and evaluated both in vitro and in vivo. [13] [14] [15] [16] [17] [18] Both ITs have anti-tumor activity in patients with B-lineage NHL. 4, 5, 10, 11, 19 The purpose of this study was to determine the cytotoxicity of these two ITs against childhood B-lineage ALL. 
Materials and methods

Cells
The human NALM-6-UM1 pre-B ALL cell line 20 was maintained by serial passages in RPMI-1640 medium (GIBCO Laboratories, Grand Island, NY, USA) containing 25 mm Hepes, 10% heat-inactivated fetal bovine serum (FBS), 100 units/ml penicillin, 100 g/ml streptomycin, and 100 m glutamine. The cells were grown in a humidified atmosphere of 5% CO 2 and air. Cell viability was determined by trypan blue exclusion.
Pre-B ALL lymphoblasts from patients were obtained from the Pediatric Oncology Group (POG) Cell Bank maintained at St Jude Children's Research Hospital, Memphis, TN, USA. Bone marrow samples were also collected from newly diagnosed patients at the Children's Medical Center of Dallas according to a protocol approved by the Institutional Review Board at the University of Texas Southwestern Medical Center at Dallas. Informed consent was obtained for each specimen received. Bone marrow aspirates were drawn in a heparinized syringe and evaluated in the clinical flow cytometry laboratory. Prior to staining, erythrocytes were lysed using an ammonium chloride solution. The samples were then washed twice with phosphate buffered saline (PBS) containing 0.05% sodium azide and 0.1% bovine serum albumin (PAB) and resuspended in 5% newborn calf serum (NCS) in RPMI-1640 tissue culture media. 500 000 cells were added to each tube. Cells were again washed with PAB, and HD37, RFB4, or an IgG1 control Mabs (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) were added. The cells were incubated in the dark for 20 min at 2-8°C, washed in PAB, and then incubated in the dark with a secondary FITC-conjugated goat anti-mouse Ig antibody (Becton Dickinson) for 20 min at 2-8°C. Cells were again washed in PAB and resuspended in 1% paraformaldehyde in PBS and analyzed on a FACSCalibur (Becton Dickinson) using CELLQuest software (Becton Dickinson). Data were analyzed using Paint-a-Gate software (Verity House, Topsham, ME, USA). The blast population was identified by forward and orthogonal light scatter. The specific mean fluorescence intensity (MFI) was calculated by subtracting the MFI of the cells incubated with the isotypicmatched control Mab from that of the cells incubated with HD37 or RFB4.
A second specimen was diluted with an equal amount of RPMI-1640 (no additives), layered over 3 ml of Isolymph (Gallard-Schlesinger, Carle Place, NY, USA) and centrifuged for 30 min at room temperature at 570 g. The layer of mononuclear cells was removed and washed three times in PBS and once in AIM-V (Gibco) serum-free media. The pellet was resuspended in freezing medium containing 10% bovine serum albumin (BSA) in AIM-V with 7.5% dimethyl sulfoxide (DMSO). The cells were counted, aliquoted in 1.0 ml at 5 × 10 6 cells/ml, and frozen in a controlled rate freezing con-Leukemia tainer to −84°C, and then to −140°C. Cell viability, as determined by trypan blue exclusion, consistently exceeded 95% prior to freezing. As required, a 1 ml aliquot of cells was thawed, washed and then resuspended in AIM-V. The cells were counted, and 1 × 10 5 cells were plated into wells of a flat-bottomed 96 well microtiter plate (Costar, Cambridge, MA, USA) containing the previously prepared bone marrow feeder layers. The viability of the leukemic cells was determined daily by trypan blue exclusion. Once the viability of the cells was stable for at least 24 h (usually on day 4), they were treated with the different concentrations of the ITs. Cell viability on day 4 ranged from 37 to 98% (mean 88%).
Stromal feeder layers
Since B-lineage ALL cells undergo apoptosis in vitro, it was essential to develop a culture system which would allow the cells to remain viable for several days. We therefore used a method described by Campana et al 21 to maintain leukemic blasts on bone marrow-derived stromal cells in serum-free medium.
To obtain bone marrow stromal cells we used either bone marrow samples from healthy donors that had been previously frozen or we collected fresh aspirates. The mononuclear cell layer was prepared as described above. Cells were washed once in complete medium, and then they were resuspended at approximately 1 × 10 7 cells/ml in freezing medium containing 85% FBS and 15% DMSO. Cells were then frozen at a controlled rate to −84°C and then to −140°C. When required, one aliquot was thawed and washed once in complete medium and centrifuged at 300 g. The cell pellet was then resuspended in 5 ml of the same medium containing 10 −6 m hydrocortisone (Sigma, St Louis, MO, USA). The cells were plated in 25 cm 2 flasks (Becton Dickinson, Franklin Lakes, NJ, USA) and cultured at 37°C in a humidified atmosphere of 5% CO 2 and air. One-half of the hydrocortisone-containing medium was changed weekly for 1 month at which time a confluent layer of stromal cells was present. Other investigators have demonstrated that this stromal layer is a mixture of fibroblasts, macrophages, reticular cells, and adipocytes. 22 The stromal layer was treated with 0.05% trypsin (Gibco) for 5 min and the cells in suspension were counted. 2 × 10 4 cells were placed into wells of a flat-bottomed 96-well microtiter plate. After 4 days, the stromal layer was washed five times with RPMI-1640 medium (no additives) and twice with AIM-V medium. 100 l of this medium was left in each well. After 24 h, the leukemia cells were added.
Treatment with ITs
The pre-B ALL cells were evaluated for their sensitivity to each of two ITs, HD37-dgRTA and RFB4-dgRTA. The ITs were prepared in our laboratory as previously described. 13 Isotype matched (IgG 1 ) irrelevent ITs (3F12-dgRTA or MOPC-21-dgRTA) were used as negative controls. The leukemic blasts were treated 4 days after they had been cultured on the stromal cell layer when the viability had stabilized at an optimal level. For the HD37-dgRTA and RFB4-dgRTA we tested IT concentrations ranging from 10 −7 to 10 −12 m. For the Combotox (a 50/50 mixture of the two) we tested IT concentrations ranging from 10 −8 to 10 −12 m. The dilutions were prepared in AIM-V medium. 100 l of each of the three agents plus medium alone (negative control) were added in triplicate to the 96-well plates containing the stromal layer.
Assessment of cytotoxic effect by flow cytometry
After 48 h of incubation, the cells were resuspended, washed once in 500 l of 2% BSA in PBS (PBSA), centrifuged for 5 min at 290 g and the supernatant was aspirated. Cells were then resuspended in 50 l of PBSA. 5 l of FITC-conjugated anti-CD10, CD19, or CD22 (Dako, Carpinteria, CA, USA) was added and the cells were incubated on ice in the dark for 30 min. Cells were then washed twice, resuspended in 300 l of PBSA, and transferred to 12 × 75 mm Falcon tubes (Becton Dickinson, Lincoln Park, NJ, USA). One drop of PI (0.25 mg/ml); (Sigma) was added just prior to analysis on the FACScan flow cytometer and data were analyzed using Cell Quest software (Becton Dickinson). From the dot plot we identified the PI − viable cells which stained with either FITCconjugated anti-CD10, anti-CD19, or anti-CD22. The cytotoxic effect was determined by two different methods: (1) 5000 (2) to account for lysed cells we also determined the number of cells acquired during a 1 min time interval. The concentration of the IT vs the percent of viable cells relative to the control was graphed using a Sigma Plot (Jandel Scientific, San Rafael, CA, USA) software program.
Results
Cytotoxic effect of ITs on the NALM-6 cell line
We first examined the cytotoxic effect of the individual ITs and Combotox on the pre-B ALL cell line, NALM-6 as shown in Figure 1 . The individual ITs as well as Combotox killed the
Figure 1
The cytotoxicity of HD37-dgRTA, and RFB4-dgRTA on Nalm-6 cells. 5 × 10 4 Nalm-6 cells were cultured in triplicate for 48 h at 37°C in a humidified atmosphere of 5% CO 2 . 5000 events were recorded. The percentage of viable cells in the treatment group vs control (no treatment) was determined by dividing the number of PI 
Characteristics of pre-B ALL cells from patients
Pre-B ALL blasts from 30 different patients were assessed for their sensitivity to the ITs. Detailed information on the immunological profiles of the patients was available for the 20 children diagnosed at our center. The age of the patients ranged from 1 to 19 years, with a mean of 6.6 years. The percentage of lymphoblasts in the bone marrow aspirates ranged from 50 to 95% (mean 81%). The cells from all patients reacted with the HD37 and RFB4 Mabs. The percentage of cells expressing CD19 and CD22 ranged from 28 to 96% (mean 73%), and 7.6 to 96.5% (mean 51%), respectively. All cells were CD10 (CALLA) + surface Ig − , and were either CD34
+ or Tdt + confirming that they were pre-B ALL cells. The leukemic blasts retained expression of CD19, CD22, and CD10 Mabs after 6 days of culture.
Cytotoxic effect of ITs on pre-B ALL cells from patients
The cytotoxicity of HD37-dgRTA was reproducible and dose dependent with an average IC 50 of 3 × 10 −9 m (Figure 2a) . Treatment with the control IT even at the highest concentrations (10 −7 -10 −8 m) had little effect on the cells. The differences in cytotoxicity between the control and HD37-dgRTA were statistically significant (P Ͻ 0.0001). Following treatment with HD37-dgRTA, the percentage of leukemic cells which remained alive reached a minimum mean of 27% (range 17-40%).
When the percentage of viable cells was determined by an alternative method that accounted for the lysis of cells during treatment, the percent of remaining viable leukemic cells was 10% (range 5-20%) (data not shown). Although the RFB4-dgRTA was less cytotoxic to the pre-B ALL cells, it killed the cells in a dose-dependent fashion. The percent of remaining viable leukemic cells was 53% (range 30-80%) (Figure 2b) . When higher concentrations were tested, they were no more effective. Despite this, there remained a significant difference in the cytotoxic effect of the RFB4-dgRTA vs the control IT (P Ͻ 0.005). Treatment of the cells with Combotox was also dose-dependent and resulted in greater cytotoxicity with an average IC 50 of 1.5 × 10 −10 m (Figure 2c ). This value was significantly different (P Ͻ 0.0005) from the IC 50 obtained using HD37-dgRTA alone. When the percentage of cells remaining alive was determined by the time interval method, the minimum percentage of viable leukemic cells was 10% (range 2-32%). The average IC 50 for each of the agents obtained by both methods is summarized in Table 1 .
Prior to treatment, the percentage and MFI of cells that expressed CD19 and CD22 was determined. The expression of CD22 on the patient specimens varied markedly. A weak correlation between the MFI of CD22 and the cytotoxic effect of RFB4-dgRTA occurred only at 10 −9 and 10 −10 m (Figure 3a) . In contrast to CD22, there was marked homogeneity in the expression of CD19. However, there was no correlation between the MFI of CD19 and the cytotoxic effect of HD37-dgRTA (Figure 3b ).
Leukemia
Figure 2
The cytotoxicity of ITs on pre-B ALL cells. 1 × 10 5 pre-B ALL cells from patients were cultured in triplicate for 48 h at 37°C in a humidified atmosphere of 5% CO 2 . 5000 events were recorded. The percentage of viable cells in the treatment group (¼) vs control (no treatment) () was determined by dividing the number of PI 
Discussion
Both HD37-dgRTA and RFB4-dgRTA have been extensively tested in vitro and in vivo for their ability to kill B-lineage lymphoma cells, [13] [14] [15] [16] [17] [18] 23 but prior to this study these ITs had not been tested on cells obtained from children diagnosed with pre-B ALL. The objective of this study was to determine whether these two ITs, which have been used to treat over 200 adult patients with NHL, would also be effective in killing precursor B-ALL cells. Therefore, we tested these agents on bone marrow aspirates from children with newly diagnosed pre-B ALL. The concentration of the ITs tested were within the range present in the sera of adult patients with NHL who had previously been enrolled in our phase I clinical trials to evaluate these ITs. 4, 5, 10, 11, 19 The major findings to emerge from this study are as follows: (1) The use of bone marrow stroma in cell culture and flow cytometry to analyze the effects of ITs indicated specific killing of the tumor cells. 2 The cytotoxic effect of HD37-dgRTA was specific and reproducible at all concentrations tested. 3 The cytotoxic effect of RFB4-dgRTA was also specific and reproducible at low but not high concentrations. As described previously, 13 RFB4-dgRTA was more potent than HD37dgRTA. (4) Combotox was more effective than either of the two ITs alone.
The CD19 antigen is a good target because it is present on virtually all early B-lineage cells. 24 The expression of CD19 is restricted to normal and neoplastic B cells.
24 CD19 is also expressed by the majority of B cell lineage malignancies, including most acute lymphoblastic leukemias. 25 Most importantly, it is not present on pluripotent stem cells.
24 CD19 is also rarely lost during neoplastic transformation, 26 and it would be unusual for a patient to present with a B-lineage neoplasm that is refractory to a CD19 IT. The mean percentage expression of the CD19 antigen on our specimens was 73%, as compared to 51% for the CD22 antigen. The cytotoxic effect of HD37-dgRTA was very reproducible, and in all cases, was significantly greater than that of the control IT. This result is probably a reflection of the consistently higher percentage of cells that were CD19 + . Although we would have anticipated that specimens containing a higher percentage of CD19 + cells with a higher MFI would be more sensitive to HD37-dgRTA, this was not the case. This is not unusual since leukemic cells can be sensitive to an IT even when the expression of the targeted antigen is very low. 27 Hence, the sensitivity of blast cells may depend not only on the expression of the antigen, but also upon the ability of the IT to be endocytosed and for the dgRTA to translocate into the cytosol. The data reflect the percentage of cells that remained alive after treatment over those that were dead because we were concerned that dead or dying cells would no longer express their surface antigens. For those cells treated with the HD37-dgRTA, we analyzed cells with FITC-RFB4, and FITC anti-CD10. The percentage of positive cells was similar regardless of the Mab used.
The CD22 antigen is less panspecific for normal B cells and is expressed only on late pre-B cells and resting B cells. 24 About 60-70% of B cell leukemias and lymphomas express CD22. 24 The percentage of pre-B ALL cells from patients that expressed CD22 was lower (51%). Since 49% of cells did not express CD22, we could not eliminate more than 51% of the leukemic blasts. Accordingly, we did approach an IC 50 value. However, lower concentrations of the RFB4-dgRTA induced a greater cytotoxic effect when compared to the HD37-dgRTA, demonstrating that RFB4-dgRTA is a more potent IT, as previously reported. 13 Our results demonstrate that by combining these two agents we were able to take advantage of the larger number of cells that were sensitive to HD37-dgRTA and the increased potency of RFB4-dgRTA. This was reflected in the 20-fold lower IC 50 of Combotox vs either IT alone (3 × 10 −9 vs 1.5 × 10
−10
). Indeed, when Combotox was used to treat SCID mice with disseminated human B cell lymphoma, a synergistic cytotoxic effect was observed. 17 Other investigators have reported similar findings using different ITs. 28 Hence, low expression of both antigens may make cells more amenable to killing by Combotox than by the individual ITs.
Historically, it has been difficult to evaluate the cytotoxic effect of potential anti-cancer agents on acute lymphoblastic leukemia because leukemic blasts die by apoptosis within 72 h. 29 Manabe et al 29 showed that apoptosis could be avoided by seeding B-lineage leukemia cells on to BM stromal cells. This method has been used to test various chemotherapeutic agents but has not been used previously to test the cytotoxic effect of ITs. The importance of the stroma in maintaining the viability of the leukemic blasts was evident from the following observations: (1) The irrelevant IT was marginally cytotoxic to the leukemic blasts, and this could have been due to an adverse effect on the stromal cells; and (2) microscopic evaluation of the stromal cells after treatment with the irrelevant IT at high concentrations resulted in damage to the confluent layers. Morphologically the pre-B ALL blasts were loosely attached and often clustered around the stromal cells. This association may be essential for the survival of the leukemic blasts, 21 and therefore damage to the supporting cells could result in a decrease in the survival of the tumor cells. Studies in both mice and humans have shown that ITs are more effective in treating minimal residual disease, since well tolerated doses of ITs are relatively ineffective in penetrating large tumors that are poorly vascularized. 30 To date, these ITs have only been used in phase I trials to treat adults with large tumor masses, many of whom have underlying co-morbidities. Hence, ITs may be effective even in advanced childhood leukemia because of the increased accessibility of the tumor cells and generally excellent condition of other organ systems.
